Author:
Subramani Jaganathan,Shaabani Namir,Shetty Dhwani,Wu Haiwa,Kwon Sunkuk,Li Wenzhao,Yue Chanyu,Lahtz Christoph,Ramirez-Torres Adela,Zhou Heyue,Zhang Yanliang,Allen Robert,Farley Bill,Emalfarb Mark,Tchelet Ronen,Markku Soloheimo,Marika Vitikainen,Wiebe Marilyn,Huuskonen Anne,Ben-artzi Hannah,Avigdor Avi,Ji Henry,Herrmann Andreas
Abstract
ABSTRACTThe identification of a vaccination candidate against COVID-19 providing protecting activity against emerging SARS-COV-2 variants remains challenging. Here, we report protection activity against a spectrum of SARS-COV-2 and variants by immunization with protein-based recombinant RBD-C-tag administered with aluminum-phosphate adjuvant intramuscularly. Immunization of C57BL/6 mice with RBD-C-tag resulted in the in vivo production of IgG antibodies recognizing the immune-critical spike protein of the SARS-COV-2 virus as well as the SARS-COV-2 variants alpha (“United Kingdom”), beta (“South Africa”), gamma (“Brazil/Japan”), and delta (“India”) as well as wt-spike protein. RBD-C-tag immunization led to a desired Th1 polarization of CD4 T cells producing IFNγ. Importantly, RBD-C-tag immunization educated IgG production delivers antibodies that exert neutralizing activity against the highly transmissible SARS-COV-2 virus strains “Washington”, “South Africa” (beta), and “India” (delta) as determined by conservative infection protection experiments in vitro. Hence, the protein-based recombinant RBD-C-tag is considered a promising vaccination candidate against COVID-19 and a broad range of emerging SARS-COV-2 virus variants.
Publisher
Cold Spring Harbor Laboratory
Reference27 articles.
1. Development of an inactivated vaccine candidate for SARS-CoV-2
2. DNA vaccine protection against SARS-CoV-2 in rhesus macaques
3. BioNTech., P. Pfizer and BioNTech dose first participants in the U.S. as part of global COVID-19 mRNA vaccine development program. Pfizer (2020).
4. Moderna. Moderna announces first participant dosed in NIH-led phase 1 study of mRNA vaccine (mRNA-1273) against novel coronavirus. Moderna (2020).
5. Overview of Vaccine Adjuvants: Introduction, History, and Current Status;Methods Mol Biol,2017